Schmidt and colleagues [1] conducted an interrupted time-series analysis to examine the
relationship between three events and the monthly prevalence of pregnant individuals …

Objective Prenatal opioid use disorder (OUD) has significantly risen, from 3.5 to 8.2 per
1000 deliveries between 2010 and 2017. 1 In August 2017, options for the treatment of …

To the Editor: S ales of opioid medications have drastically increased in the past decade
(Dart et al., 2015). In a disturbingly parallel development, deaths from prescription opioids …

Objective To assess the cost effectiveness of buprenorphine versus methadone in the
management of opioid use disorder (OUD) during pregnancy. Methods We designed a …

Objectives Medication-Assisted Treatment (MAT), such as Buprenorphine, is recommended
for pregnant women with opioid use disorder (OUD). Without treatment, OUD can …

Background and Objectives The factors associated with medication for opioid use disorder
(MOUD) treatment retention among pregnant women with opioid use disorder (OUD) are …

Pregnant women with opioid use disorder should receive medication-assisted treatment, as
the benefits to both mother and fetus/offspring outweigh the risks. While methadone is the …

Background Opioid agonist therapy is strongly recommended for pregnant persons with
opioid use disorder. Buprenorphine may be associated with more favorable neonatal and …

METHODS: We used a theoretical cohort of 22,400 pregnant women to approximate the
number of pregnancies affected by OUD per year in the United States. Outcomes included …

Opioid misuse during pregnancy is associated with negative outcomes for both mother and
fetus due not only to the physiological effects of the drug but also to the associated social …